JPMorgan Healthcare Leaders ETF(JDOC.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
JPMorgan Healthcare Leaders ETF
JDOC.US
News
View More

AbbVie plans to build out its presence in obesity market

AbbVie is expanding its presence in the obesity treatment market by leveraging Gubra's weight-loss drug, GUBamy, which mimics the hormone amylin. This drug aims to provide an alternative to GLP-1 drugs like Wegovy and Zepbound, focusing on better tolerability and durability of weight loss. AbbVie believes its existing aesthetics business positions it well, as patients seeking cosmetic treatments are also interested in weight loss solutions. The obesity drug market is projected to reach $150 billion in annual sales within the next decade.

Reuters·
US
ABBV
-2.32%
Reuters·
US
ABBV
-2.32%

UnitedHealthcare to Support Rural Hospitals with Accelerated Medicare Advantage Payments, Providing Immediate Cash-Flow Relief

UnitedHealthcare has launched the Rural Payment Acceleration Pilot to support independent rural hospitals by accelerating Medicare Advantage payment timelines from less than 30 days to under 15 days. This initiative aims to provide immediate cash-flow relief and enhance the sustainability of these hospitals. CEO Bobby Hunter emphasized the importance of rural hospitals in communities and the goal of improving patient care. The pilot will inform future expansions to additional hospitals, reinforcing UnitedHealthcare's commitment to rural health stability.

Press Releases·
US
UNH
+1.19%
Press Releases·
US
UNH
+1.19%

Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign

AbbVie has signed a three-year deal with the U.S. government to reduce Medicaid drug prices and invest $100 billion in U.S. research and manufacturing over ten years.123Justin Kim, a former Lazard banker, faces insider trading charges linked to AbbVie's $10.1 billion ImmunoGen acquisition, allegedly profiting $41 million from leaked confidential takeover info.4The UAE's Ministry of Health has teamed up with AbbVie to launch the 'Mental Health 360' campaign, aimed at boosting mental health awareness and enhancing community well-being.5

TradingView·
US
ABBV
-2.32%
TradingView·
US
ABBV
-2.32%

BUZZ-Street View: Merck signals renewed confidence in growth after Keytruda patent loss

Merck has raised its revenue outlook to $70 billion by the mid-2030s, signaling renewed confidence despite the impending loss of its Keytruda patent, which could impact 50% of its revenue. Analysts from Bernstein, BMO Capital Markets, and Citi provided mixed reviews, with Bernstein highlighting the challenges ahead, while BMO noted a newfound confidence in Merck's strategy. Citi acknowledged progress but cautioned that Merck is not yet fully secure against the patent loss's effects.

Reuters·
US
MRK
-0.04%
Reuters·
US
MRK
-0.04%

Walmart, Johnson & Johnson Share Gains Lead Dow's 125-Point Climb

Walmart and Johnson & Johnson shares are driving the Dow Jones Industrial Average up by 129 points (0.3%) on Monday afternoon. Walmart's stock rose by $3.85 (3.4%), and Johnson & Johnson's increased by $5.39 (2.6%), contributing approximately 57 points to the index's gain. Other significant contributors include IBM, Boeing, and Caterpillar. A $1 change in any of the 30 components affects the Dow by 6.16 points.

Dow Jones·
US
WMT
-0.70%
US
JNJ
+0.47%
Dow Jones·
US
WMT
-0.70%
US
JNJ
+0.47%
© 2026 Longbridge｜Disclaimer